Antibody Drug Conjugate

Many drugs used to treat cancer have toxicities that lead to serious side effects, which limit the dose and effectiveness of these agents and place a tremendous burden on patients. One potential way to alleviate these problems is through an antibody-drug conjugate (ADC).

An ADC is engineered by linking cytotoxic cancer drug molecules to antibodies or antibody fragments. The antibody portion of the ADC can be designed to target specific proteins found primarily on tumor cells. The goal is to deliver the cytotoxic payload more directly to tumor cells and reduce the collateral damage to healthy tissue. Both parts of an ADC—the targeting region and the payload—can be altered to target different types of tumors with different cancer drugs.

An antibody-drug conjugate is designed to deliver the cytotoxic payload of an anti-cancer more directly to tumor cells, which can reduce collateral damage to healthy tissue.

Subscribe for the latest from Amgen Science.

System error message. Lorem ipsum.
I authorize Amgen and its contractors to use my email address and provide me with updates, informational material, and/or contact me about Amgen Science. I understand that my email address will not be used for any other purposes. I understand that receiving these communications is optional and free and that I have the ability to opt out at anytime. For more information, please see the Amgen privacy policy.